$4.705
-0.187 (-3.98%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
IVA Prediction & Forecast by Similar Chart Analysis
Alphio's IVA stock price prediction model matches the current Inventiva SA tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $4.62 (-1.86%). The 1-week path is $4.57 (-2.96%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Inventiva SA Stock?
Inventiva SA (IVA) presents a compelling buying opportunity at the current price of $4.705, especially considering the upcoming Phase 3 trial results for lanifibranor, expected in Q4 2026. The stock has shown a 5.02% increase over the last 20 days, indicating positive momentum. Moreover, hedge funds have increased their buying activity by 681.82% over the last quarter, suggesting strong institutional interest. However, the company reported no revenue for Q1 2026, which remains a significant risk to its financial stability.
IVA stock price ended at $4.71 on Friday, after losing -3.98%
Inventiva SA (IVA) last closed at $4.705, losing -3.98%. These facts feed the 1-day and 1-week IVA price prediction above.
Forecast Drivers
Inventiva SA (IVA) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches IVA, ranked by similarity.
Seasonality analysis for IVA
Historically the probability of a positive August return for IVA is 38.10%. March offers the highest probability of a positive month at 68.25%, while July is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.